Latest / The Series A Show with Fexingo: Early-Stage Funding, Pitch Decks, and Startup Milestones / Why Startups Are Using Pre-Filled Drug Trials
Transcript
- Lucas: So ARKG, the genomics ETF, is up more than 17 percent over the past five days. That's a pretty loud signal that investors are circling back toward biotech after a pretty rough 2024 and '25. Luna: Yeah, we've seen a few big biotech IPOs in the first half of this year — but the window is still narrow. Most startups can't afford to wait. Lucas: Right, and that's exactly why we're seeing a new approach in early-stage biotech fundraising: pre-filled drug trials. The idea is you don't start from scratch. You buy or license partially completed clinical data — from a university lab, a contract research organization, sometimes even a bankrupt competitor — and you use that existing data to launch your own trial or go straight to Series A. Luna: Wait — so you're skipping the 'let's run our own Phase 1' step? That feels risky from a regulatory standpoint. Lucas: It is risky. But the economics are compelling. A typical biotech startup needs to raise anywhere from 10 to 20 million dollars just to get through Phase 1 on a single asset. If you can license a data package that already has safety data from 20 or 30 patients, you can cut that timeline by 12 to 18 months and reduce your capital requirements by maybe 40 percent. Luna: And that's the difference between closing a Series A in 2026 and being stuck in pre-seed limbo. Lucas: Exactly. There's a real-world case from April 2026: a startup called Synapsis Bio raised an 18-million-dollar Series A. Their lead asset was a neuropathic pain compound. They didn't discover it. They licensed Phase 1 data from a shelved program at Stanford. The original trial had been halted for non-safety reasons — the lead investigator left academia — so the data was clean. Luna: And the investors bought it? I mean, that's not exactly a clean slate. Lucas: They did. The lead investor told me the data package included full safety readouts, pharmacokinetic profiles, even some biomarker signals. That's more than most startups have when they walk into a Series A pitch. The risk was that the FDA might not accept the data — but Synapsis Bio structured the deal so that they would get a first-in-human trial waiver if the agency pushed back. Luna: So they had a backup plan. But what about the legal side? Patient consent forms from a prior trial — are they transferable? Lucas: That's the gray area. In Synapsis's case, the original consent forms at Stanford were written broadly enough to allow data sharing with commercial entities. But not all academic consent forms are that permissive. A lot of them say 'this data will be used for research purposes only.' If you're a for-profit startup, you can't touch that. Luna: That's a huge due diligence hurdle. I'd want to see the actual consent form before I wrote a check. Lucas: Absolutely. And some VCs are ahead of this. A few firms now have legal templates they ask startups to use when negotiating data licensing from universities — essentially a pre-approved consent framework. It's still early, but it's becoming a standard clause in term sheets. Luna: Speaking of early — I'm curious about the broader trend. Is this just a way to bridge the current IPO gap, or do you see pre-filled trials becoming the default way to launch a biotech startup? Lucas: I think it's more than a bridge. The cost of running trials has gone up, and the success rates haven't. If you can take a derisked data set and raise a Series A in six months instead of 18, that's a structural advantage. But there's a risk: if everyone starts trading the same data packages, you could end up with a 'lemons problem' — only the problem assets get sold, and the good data gets held by pharma companies that don't need to license it out. Luna: So the market could bifurcate: high-quality data stays in-house, and startups get the leftovers. Lucas: That's the worry. But for now, we're in the early adopter phase. The ARKG numbers suggest the market is rewarding biotech innovators. And pre-filled trials are one of the clearest signs that founders are getting creative about capital efficiency. Luna: Yeah, I think that's a good place to land. If these conversations are useful for what you're building or running — and they help you think about capital strategy differently — consider supporting the show. It's listener-supported, ad-free, and keeps going because people like you chip in. You can find us at buy me a coffee dot com slash fexingo. Lucas: And that support really does make a difference. Now back to the data angle — I want to talk about how investors are actually valuing these pre-filled data packages. Because it's not like buying a used car. Luna: No, the valuation methodology is fascinating. How do you price a Phase 1 data set? Is it based on the original cost? The probability of success? Comparable deals? Lucas: Mostly comparable deals. There's a small but growing market: data packages from shelved pharma programs, academic labs, even CROs that ran trials for failed startups. The typical range for a Phase 1 data set with 20 to 30 patients is 500,000 to 2 million dollars. But if the data includes biomarker or imaging evidence, the price can go higher. Luna: And that's a fraction of what it would cost to run the trial yourself. Lucas: Exactly. The startup I mentioned — Synapsis Bio — paid about 1.2 million for the Stanford data. That's less than what they would have spent on a single manufacturing run. And it got them to a Series A in under a year. Luna: But what about the FDA? You mentioned the waiver option. How often does the agency actually accept data from a prior trial? Lucas: It's case by case. The FDA has guidelines for data transferability, but they're not black and white. If the original trial was conducted under an fda recognized good clinical practice — and the consent forms are transferable — they usually accept it. But if there's a change in the patient population or the dosing regimen, they may require a bridging study. That adds time and cost. Luna: So the diligence isn't just legal — it's also regulatory. You need someone who knows the FDA's mind. Lucas: Right. And that's why some VCs are building in-house regulatory expertise or partnering with consultants. One firm I know has a part-time former FDA reviewer who vets every data package before they invest. Luna: That's smart. So this isn't just a financial innovation — it's also an operational one. Startups need to be savvy about regulatory strategy from day one. Lucas: Absolutely. And the best founders are using pre-filled data not just to save money, but to get better data. A well-run Phase 1 from a top academic center is often more rigorous than what a startup could afford on its own. Luna: So the quality can actually be higher. Lucas: In some cases, yes. Stanford, for example, has extremely high standards for data collection and monitoring. That's worth paying for. Luna: Alright, I'm sold on the concept. But I want to push on one thing: if this becomes common, won't big pharma just hoard their shelved data? They have thousands of compounds that didn't make it to market. Lucas: They already are. But the interesting thing is that some pharma companies are starting to see this as a revenue stream. If they have a compound that failed for efficacy but had clean safety data, they can license it to a startup focused on a different indication. That's a win-win — the pharma company gets cash, the startup gets derisked data. Luna: So we might see pharma companies acting more like data landlords than drug developers. Lucas: Exactly. And that could change the entire landscape of early-stage biotech. I think we're going to look back at 2026 as the year pre-filled trials went mainstream. Luna: Given the ARKG run, the market seems to agree. Lucas: Yeah. But the real test will be the next downturn. If biotech ETFs pull back and pre-filled data packages keep getting deals done, that's when you know it's not just a trend. Luna: Fair point. Until then, I'm watching the consent forms. Lucas: Always a good habit.